Pfizer Inc.

NYSE PFE

Pfizer Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 35.13

Pfizer Inc. Price to Earnings Ratio (P/E) is 35.13 on January 14, 2025, a -53.25% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Pfizer Inc. 52-week high Price to Earnings Ratio (P/E) is 75.44 on January 23, 2024, which is 114.72% above the current Price to Earnings Ratio (P/E).
  • Pfizer Inc. 52-week low Price to Earnings Ratio (P/E) is -565.70 on May 22, 2024, which is -1,710.18% below the current Price to Earnings Ratio (P/E).
  • Pfizer Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -122.42.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: PFE

Pfizer Inc.

CEO Dr. Albert Bourla D.V.M., Ph.D.
IPO Date June 1, 1972
Location United States
Headquarters 235 East 42nd Street
Employees 88,000
Sector Health Care
Industries
Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Similar companies

MRK

Merck & Co., Inc.

USD 99.65

-1.32%

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

JNJ

Johnson & Johnson

USD 144.75

0.19%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email